Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC (Frontiers in Oncology, (2024), 14, (1460150), 10.3389/fonc.2024.1460150)

Meidenbauer J, Wachter M, Schulz S, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipl U, Jost T (2025)

Publication Language: English

Publication Type: Journal article, Erratum

Publication year: 2025

Journal

Frontiers in Oncology Frontiers Media

Book Volume: 15

Article Number: 1607882

DOI: 10.3389/fonc.2025.1607882

Abstract

In the published article, there was an error in the Funding statement. In the Funding statement one sentence was missing. The correct Funding statement appears below. “The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the DFG Doctoral Training Group 2599 “Fine-Tuners of the Adaptive Immune Response” and partly by the Interdisciplinary Center for Clinical Research (IZKF) in Erlangen. The present work was performed by Julia Meidenbauer in (partial) fulfilment of the requirements for obtaining the degree “Dr. med.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Authors with CRIS profile

Julia Meidenbauer Department of Radiation Oncology Matthias Wachter Department of Radiation Oncology Sebastian Schulz Department of Molecular Immunology Benjamin Frey Department of Radiation Oncology Rainer Fietkau Lehrstuhl für Strahlentherapie Udo Gaipl Department of Radiation Oncology Tina Jost Department of Radiation Oncology

How to cite

APA:

Meidenbauer, J., Wachter, M., Schulz, S., Mostafa, N., Zülch, L., Frey, B.,... Jost, T. (2025). Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC (Frontiers in Oncology, (2024), 14, (1460150), 10.3389/fonc.2024.1460150). Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1607882

MLA:

Meidenbauer, Julia, et al. "Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC (Frontiers in Oncology, (2024), 14, (1460150), 10.3389/fonc.2024.1460150)." Frontiers in Oncology 15 (2025).

BibTeX: Download